文献速递肝病消化道肿瘤与早癌

NLRP6缺陷通过E-Syt1增强巨噬细胞吞噬作用抑制肝细胞癌进展

NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression.
PubMed 文献 · Gut · 2025-10-08

本研究探讨巨噬细胞NLRP6在肝细胞癌进展中的作用及治疗潜力。在患者样本中检测到CD68和NLRP6表达,巨噬细胞NLRP6低表达者生存期更长;Nlrp6-/-小鼠及巨噬细胞特异性Nlrp6敲除小鼠肿瘤生长延迟,过继转移Nlrp6-/-巨噬细胞可减少肿瘤生长;NLRP6通过PYD结构域与E-Syt1 SMP结构域相互作用负调控吞噬。结论:NLRP6通过抑制巨噬细胞浸润和吞噬促进肝细胞癌进展,转移Nlrp6-/-巨噬细胞是减少肿瘤生长的有前景的治疗策略。

要点

  • 患者肝细胞癌组织中巨噬细胞NLRP6低表达与更长生存期相关。
  • Nlrp6-/-小鼠及巨噬细胞特异性Nlrp6敲除小鼠较野生型小鼠肿瘤生长延迟。
  • 过继转移Nlrp6-/-巨噬细胞可减少体内肿瘤生长。

核心结论

  • NLRP6通过其PYD结构域与E-Syt1的SMP结构域相互作用,抑制巨噬细胞浸润和吞噬作用,从而促进肝细胞癌进展。
  • 转移Nlrp6-/-巨噬细胞是减少肝细胞癌肿瘤生长的有前景的治疗策略。

研究设计与样本

  • 对患者样本进行免疫荧光染色。
  • 建立自主、原位、皮下肝肿瘤模型,在野生型、Nlrp6-/-小鼠及细胞特异性Nlrp6敲除小鼠中进行RNA测序、流式细胞术和免疫组化。
  • 使用颗粒或肿瘤细胞评估吞噬作用。
  • 采用多组学、免疫沉淀质谱、 western blot和免疫共沉淀检测NLRP6的PYD结构域与E-Syt1的SMP结构域之间的相互作用。

主要发现

  • 患者肝细胞癌组织中检测到CD68(巨噬细胞标志物)和NLRP6表达,巨噬细胞NLRP6表达较低的患者生存期更长。
  • 与野生型小鼠相比,Nlrp6-/-小鼠和巨噬细胞细胞特异性Nlrp6敲除小鼠显示肿瘤生长延迟。
  • 过继转移Nlrp6-/-巨噬细胞减少体内肿瘤生长。
  • 来自Nlrp6-/-小鼠的巨噬细胞较野生型小鼠更丰富且表现出增强的吞噬作用。
  • 免疫共沉淀和吞噬实验显示E-Syt1促进吞噬作用,而NLRP6通过与其PYD结构域相互作用负调控该过程。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current treatments with tyrosine kinase inhibitors and immune checkpoint inhibitors have limited efficacy for hepatocellular carcinoma (HCC) due to drug resistance. Emerging therapies such as chimeric antigen receptor T (CAR-T) and macrophage-based cell therapies are promising but need to be improved. OBJECTIVES: This study investigates the role of macrophage NOD-like receptor family pyrin domain containing 6 (NLRP6) in HCC progression and its therapeutic potential. DESIGN: Immunofluorescence staining was performed in patient samples. Liver tumour models (autonomous, orthotopic, subcutaneous) were developed, and RNA sequencing, flow cytometry and immunohistochemistry were performed in wild-type, Nlrp6 -/- mice, and cell-specific Nlrp6 knockout mice. Phagocytosis was assessed using particles or tumour cells. Multiomics, immunoprecipitation mass spectrometry, western blot and co-immunoprecipitation were performed to examine the interaction between NLRP6's PYD domain and E-Syt1's SMP domain. RESULTS: CD68 (a macrophage marker) and NLRP6 expression were detected in patient HCC tissues, and patients with lower macrophage NLRP6 expression had longer survival. Compared with their wild-type mice, Nlrp6 -/- mice and macrophage cell-specific Nlrp6 knockout mice showed delayed tumour growth. Adoptive transfer of Nlrp6 -/- macrophages reduced tumour growth in vivo. Macrophages from Nlrp6 -/- mice were more abundant and exhibited enhanced phagocytosis compared with those from wild-type mice. Co-immunoprecipitation and phagocytosis experiments revealed E-Syt1 promoted phagocytosis, which was negatively regulated by NLRP6 through interaction with its PYD domain. CONCLUSIONS: NLRP6 promotes HCC progression by inhibiting macrophage infiltration and suppressing phagocytosis via the interaction between its PYD domain and E-Syt1's SMP domain. Transfer of Nlrp6 -/- macrophages is a promising therapeutic strategy for reducing HCC tumour growth.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Li S, Fu Y, Jia X, et al. NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression. Gut. 2025. PMID: 40473401. doi:10.1136/gutjnl-2024-334448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。